ELUT
What one share of Elutia holds
Biological Products, (No Diagnostic Substances)
At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. We develop proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients.
Elutia’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.27 |
|---|---|
| Profit | $1.01 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$1.01 |
| Cash and investments | $0.45 |
| Debt | $0.70 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $66.41 | −$18.48 | $0.89 | −$12.08 | — | −$85.01 |
| 2020 | $14.96 | −$8.88 | $0.22 | −$5.00 | — | $7.30 |
| 2021 | $4.54 | −$2.38 | $0.04 | −$1.51 | — | $1.29 |
| 2022 | $1.72 | −$2.38 | $0.04 | −$1.59 | — | −$0.36 |
| 2023 | $1.36 | −$2.07 | $0.02 | −$1.22 | — | −$2.13 |
| 2024 | $0.50 | −$1.86 | $0.02 | −$0.80 | — | −$1.59 |
| 2025 | $0.27 | $0.87 | $0.04 | −$1.02 | — | $0.67 |